Columbus Circle Investors’s Ultragenyx Pharmaceutical RARE Stock Holding History

Columbus Circle Investors’s Portfolio RARE Stock Details RARE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q4	$8.31M	Buy	60,022 +7,708	+15%	+$914K	0.36%	97
2020 Q3	$4.3M	Buy	+52,314	New	+$4.34M	0.19%	119
2017 Q1	–	Sell	-118,843	Closed	-$8.36M	–	306
2016 Q4	$8.36M	Sell	118,843 -44,388	-27%	-$3.15M	0.11%	163
2016 Q3	$11.6M	Sell	163,231 -22,784	-12%	-$1.45M	0.13%	145
2016 Q2	$9.1M	Sell	186,015 -50,180	-21%	-$3.25M	0.09%	176
2016 Q1	$15M	Buy	236,195 +185	+0.1%	+$12.1K	0.13%	142
2015 Q4	$26.5M	Buy	236,010 +85,781	+57%	+$8.58M	0.21%	109
2015 Q3	$14.5M	Buy	+150,229	New	+$17.2M	0.12%	159
2015 Q2	–	Sell	-21,428	Closed	-$1.33M	–	303
2015 Q1	$1.33M	Sell	21,428 -6,609	-24%	-$367K	0.01%	259
2014 Q4	$1.23M	Buy	+28,037	New	+$1.28M	0.01%	256

Other funds holding RARE

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

ClearBridge Investments New York $121B AUM 27.52% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Alkeon Capital Management New York $74.1B AUM 71.18% 1-Year Est. Return

Columbus Circle Investors's RARE Position: Q4 2020 in Review

Columbus Circle Investors increased its Ultragenyx Pharmaceutical (RARE) stake by 15% in Q4 2020, buying an estimated $914K and bringing the position to 60,022 shares worth $8.31M. The position accounts for 0.36% of the portfolio, ranked #97.

Columbus Circle Investors first reported a position in RARE in Q4 2014 and has held it in 10 quarters since. The position peaked at $26.5M in Q4 2015. 253 funds tracked by Wall St. Rank hold RARE as of Q4 2020.

Columbus Circle Investors held 60,022 shares of Ultragenyx Pharmaceutical worth $8.31M as of Q4 2020.
Columbus Circle Investors bought 7,708 Ultragenyx Pharmaceutical shares in Q4 2020, an estimated $914K.
Ultragenyx Pharmaceutical made up 0.36% of Columbus Circle Investors's portfolio in Q4 2020, its #97 holding.
Columbus Circle Investors first reported a position in Ultragenyx Pharmaceutical in Q4 2014 and has held it in 10 quarters since.
Columbus Circle Investors's Ultragenyx Pharmaceutical position peaked at $26.5M in Q4 2015.
253 funds tracked by Wall St. Rank held Ultragenyx Pharmaceutical as of Q4 2020.

Based on Columbus Circle Investors's 13F filing for Q4 2020, filed 20 Jan 2021.